The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-06-05

AUTHORS

Samuel J. P. Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova, Barnaby Hunt

ABSTRACT

IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with improved glycemic control and reduced body mass index (BMI) versus once-weekly GLP-1 receptor agonist dulaglutide in SUSTAIN 7, which is reimbursed in patients with a BMI > 35 kg/m2 in Slovakia. The aim of the present study was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus dulaglutide 1.5 mg in Slovakia.MethodsClinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m2 in SUSTAIN 7. Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin. Treatment effects associated with once-weekly semaglutide and dulaglutide were maintained for the first 3 years before HbA1c increased to 7.0% and BMI reverted to baseline. Costs were accounted from a healthcare payer perspective in Slovakia and expressed in euros (EUR). Utilities relating to quality of life were taken from published sources.ResultsOnce-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg. Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg. Both doses of once-weekly semaglutide were therefore considered dominant versus dulaglutide 1.5 mg.ConclusionBoth doses of once-weekly semaglutide represent cost-saving treatment options versus dulaglutide 1.5 mg for obese patients with type 2 diabetes in Slovakia.FundingNovo Nordisk A/S. More... »

PAGES

2034-2051

References to SciGraph publications

  • 2013-06-03. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2001-09. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes in DIABETOLOGIA
  • 2018-04-19. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs in DIABETES THERAPY
  • 2015-01-13. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes in DIABETOLOGIA
  • 2014-05-17. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries in QUALITY OF LIFE RESEARCH
  • 2002-05-24. Revealing the cost of Type II diabetes in Europe in DIABETOLOGIA
  • 2017-02-21. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain in DIABETES THERAPY
  • 2009-08-14. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial in DIABETOLOGIA
  • 2004-10-27. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) in DIABETOLOGIA
  • 2019-03-29. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada in PHARMACOECONOMICS - OPEN
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12325-019-00965-y

    DOI

    http://dx.doi.org/10.1007/s12325-019-00965-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1116668545

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31168765


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Administration Schedule", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glucagon-Like Peptides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypoglycemic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Slovakia", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Malkin", 
            "givenName": "Samuel J. P.", 
            "id": "sg:person.012067446720.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Russel-Szymczyk", 
            "givenName": "Monika", 
            "id": "sg:person.01340720514.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340720514.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pharm-In spol. s.r.o, Bratislava, Slovakia", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Pharm-In spol. s.r.o, Bratislava, Slovakia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Psota", 
            "givenName": "Marek", 
            "id": "sg:person.01024046656.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024046656.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Slovakia s.r.o, Bratislava, Slovakia", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Slovakia s.r.o, Bratislava, Slovakia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hlavinkova", 
            "givenName": "Lucia", 
            "id": "sg:person.0670735136.94", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670735136.94"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hunt", 
            "givenName": "Barnaby", 
            "id": "sg:person.01346701147.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1477-7525-11-90", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013049175", 
              "https://doi.org/10.1186/1477-7525-11-90"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-004-1527-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036304902", 
              "https://doi.org/10.1007/s00125-004-1527-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-017-0239-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083855326", 
              "https://doi.org/10.1007/s13300-017-0239-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s41669-019-0131-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113109417", 
              "https://doi.org/10.1007/s41669-019-0131-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/pl00002934", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048891551", 
              "https://doi.org/10.1007/pl00002934"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-014-3460-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015538250", 
              "https://doi.org/10.1007/s00125-014-3460-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-002-0858-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015709744", 
              "https://doi.org/10.1007/s00125-002-0858-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-009-1472-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013300593", 
              "https://doi.org/10.1007/s00125-009-1472-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-018-0424-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103465312", 
              "https://doi.org/10.1007/s13300-018-0424-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11136-014-0712-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041603789", 
              "https://doi.org/10.1007/s11136-014-0712-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-06-05", 
        "datePublishedReg": "2019-06-05", 
        "description": "IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with improved glycemic control and reduced body mass index (BMI) versus once-weekly GLP-1 receptor agonist dulaglutide in SUSTAIN 7, which is reimbursed in patients with a BMI >\u200935\u00a0kg/m2 in Slovakia. The aim of the present study was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg versus dulaglutide 1.5\u00a0mg in Slovakia.MethodsClinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI >\u200935\u00a0kg/m2 in SUSTAIN 7. Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3\u00a0years, after which treatment was intensified to basal insulin. Treatment effects associated with once-weekly semaglutide and dulaglutide were maintained for the first 3\u00a0years before HbA1c increased to 7.0% and BMI reverted to baseline. Costs were accounted from a healthcare payer perspective in Slovakia and expressed in euros (EUR). Utilities relating to quality of life were taken from published sources.ResultsOnce-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07\u00a0quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5\u00a0mg. Lifetime medical costs were similar, with cost savings of EUR\u00a020 and EUR\u00a0140 per patient with once-weekly semaglutide 0.5\u00a0mg and 1\u00a0mg, respectively, versus dulaglutide 1.5\u00a0mg. Both doses of once-weekly semaglutide were therefore considered dominant versus dulaglutide 1.5\u00a0mg.ConclusionBoth doses of once-weekly semaglutide represent cost-saving treatment options versus dulaglutide 1.5\u00a0mg for obese patients with type 2 diabetes in Slovakia.FundingNovo Nordisk A/S.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12325-019-00965-y", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096634", 
            "issn": [
              "0741-238X", 
              "1865-8652"
            ], 
            "name": "Advances in Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "8", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "36"
          }
        ], 
        "keywords": [
          "body mass index", 
          "weekly semaglutide 0.5", 
          "weekly semaglutide", 
          "dulaglutide 1.5", 
          "quality-adjusted life years", 
          "SUSTAIN 7", 
          "glycemic control", 
          "GLP-1 receptor agonist dulaglutide", 
          "type 2", 
          "long-term cost-effectiveness analysis", 
          "peptide-1 receptor agonists", 
          "reduced body mass index", 
          "novel GLP-1 analog", 
          "Baseline cohort characteristics", 
          "cost-saving treatment option", 
          "GLP-1 analogues", 
          "type 2 diabetes", 
          "low hypoglycemia risk", 
          "healthcare payer perspective", 
          "quality-adjusted life expectancy", 
          "lifetime medical costs", 
          "treatment effects", 
          "quality of life", 
          "classes of treatments", 
          "cost-effectiveness analysis", 
          "multifactorial benefits", 
          "obese patients", 
          "mass index", 
          "hypoglycemia risk", 
          "treatment options", 
          "receptor agonist", 
          "IQVIA CORE", 
          "patient's lifetime", 
          "payer perspective", 
          "medical costs", 
          "dulaglutide", 
          "semaglutide", 
          "cohort characteristics", 
          "patients", 
          "cost outcomes", 
          "life years", 
          "weight loss", 
          "life expectancy", 
          "doses", 
          "present study", 
          "treatment", 
          "years", 
          "MethodsClinical", 
          "diabetes", 
          "cost savings", 
          "agonists", 
          "insulin", 
          "baseline", 
          "outcomes", 
          "risk", 
          "control", 
          "Versus", 
          "expectancy", 
          "m2", 
          "effect", 
          "options", 
          "aim", 
          "index", 
          "management", 
          "euro", 
          "study", 
          "life", 
          "benefits", 
          "loss", 
          "utility", 
          "improvement", 
          "analogues", 
          "quality", 
          "s.", 
          "analysis", 
          "characteristics", 
          "Slovakia", 
          "cost", 
          "model", 
          "perspective", 
          "class", 
          "source", 
          "savings", 
          "lifetime", 
          "core"
        ], 
        "name": "The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia", 
        "pagination": "2034-2051", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1116668545"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12325-019-00965-y"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31168765"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12325-019-00965-y", 
          "https://app.dimensions.ai/details/publication/pub.1116668545"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:39", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_801.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12325-019-00965-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-00965-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-00965-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-00965-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-00965-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    272 TRIPLES      21 PREDICATES      133 URIs      115 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12325-019-00965-y schema:about N3231159448fd4e94b93dee5768f2786a
    2 N329df857bc6e4dc5a013cea18d759328
    3 N4eb61e2871fb4701b32463e74bfb93b2
    4 N80a55e1915d74102b6d5a0be9d2d8286
    5 N9c0cf136c97b4d82ac33169b8148b7bc
    6 Na10f01d6ea9740e09f662a3c87c399b2
    7 Na37e9e308a914f60af4911b2ae55da79
    8 Nae4c0ccc6d7d428ba632c084663d5cce
    9 Nc8328a6118cd44859f00e0fb0c31bf46
    10 Nd4e02989863345c78d0dc3f3ac6023b9
    11 Nf8379dfd7a194836b900d041b8bd0984
    12 Nfde9cb48794d4828aaa403c95de304a7
    13 Nfe8b3ad33bee40fbb2de48169fa3b81d
    14 anzsrc-for:11
    15 anzsrc-for:1103
    16 schema:author N748f7a61d71a43478bafc8aa41180d23
    17 schema:citation sg:pub.10.1007/pl00002934
    18 sg:pub.10.1007/s00125-002-0858-x
    19 sg:pub.10.1007/s00125-004-1527-z
    20 sg:pub.10.1007/s00125-009-1472-y
    21 sg:pub.10.1007/s00125-014-3460-0
    22 sg:pub.10.1007/s11136-014-0712-x
    23 sg:pub.10.1007/s13300-017-0239-6
    24 sg:pub.10.1007/s13300-018-0424-2
    25 sg:pub.10.1007/s41669-019-0131-6
    26 sg:pub.10.1186/1477-7525-11-90
    27 schema:datePublished 2019-06-05
    28 schema:datePublishedReg 2019-06-05
    29 schema:description IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with improved glycemic control and reduced body mass index (BMI) versus once-weekly GLP-1 receptor agonist dulaglutide in SUSTAIN 7, which is reimbursed in patients with a BMI > 35 kg/m2 in Slovakia. The aim of the present study was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus dulaglutide 1.5 mg in Slovakia.MethodsClinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m2 in SUSTAIN 7. Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin. Treatment effects associated with once-weekly semaglutide and dulaglutide were maintained for the first 3 years before HbA1c increased to 7.0% and BMI reverted to baseline. Costs were accounted from a healthcare payer perspective in Slovakia and expressed in euros (EUR). Utilities relating to quality of life were taken from published sources.ResultsOnce-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg. Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg. Both doses of once-weekly semaglutide were therefore considered dominant versus dulaglutide 1.5 mg.ConclusionBoth doses of once-weekly semaglutide represent cost-saving treatment options versus dulaglutide 1.5 mg for obese patients with type 2 diabetes in Slovakia.FundingNovo Nordisk A/S.
    30 schema:genre article
    31 schema:isAccessibleForFree true
    32 schema:isPartOf N23e98cdd0fe745558a4a3daaa27222ea
    33 Nfd965906c81b4efcb4ccd466cf24727b
    34 sg:journal.1096634
    35 schema:keywords Baseline cohort characteristics
    36 GLP-1 analogues
    37 GLP-1 receptor agonist dulaglutide
    38 IQVIA CORE
    39 MethodsClinical
    40 SUSTAIN 7
    41 Slovakia
    42 Versus
    43 agonists
    44 aim
    45 analogues
    46 analysis
    47 baseline
    48 benefits
    49 body mass index
    50 characteristics
    51 class
    52 classes of treatments
    53 cohort characteristics
    54 control
    55 core
    56 cost
    57 cost outcomes
    58 cost savings
    59 cost-effectiveness analysis
    60 cost-saving treatment option
    61 diabetes
    62 doses
    63 dulaglutide
    64 dulaglutide 1.5
    65 effect
    66 euro
    67 expectancy
    68 glycemic control
    69 healthcare payer perspective
    70 hypoglycemia risk
    71 improvement
    72 index
    73 insulin
    74 life
    75 life expectancy
    76 life years
    77 lifetime
    78 lifetime medical costs
    79 long-term cost-effectiveness analysis
    80 loss
    81 low hypoglycemia risk
    82 m2
    83 management
    84 mass index
    85 medical costs
    86 model
    87 multifactorial benefits
    88 novel GLP-1 analog
    89 obese patients
    90 options
    91 outcomes
    92 patient's lifetime
    93 patients
    94 payer perspective
    95 peptide-1 receptor agonists
    96 perspective
    97 present study
    98 quality
    99 quality of life
    100 quality-adjusted life expectancy
    101 quality-adjusted life years
    102 receptor agonist
    103 reduced body mass index
    104 risk
    105 s.
    106 savings
    107 semaglutide
    108 source
    109 study
    110 treatment
    111 treatment effects
    112 treatment options
    113 type 2
    114 type 2 diabetes
    115 utility
    116 weekly semaglutide
    117 weekly semaglutide 0.5
    118 weight loss
    119 years
    120 schema:name The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    121 schema:pagination 2034-2051
    122 schema:productId N4f4357ffd1394a4f832527e78edccf0b
    123 N6638f62d50674f30bd0f5341cbea8cc0
    124 N818a3ee2e6de409698ca3e929279e3d9
    125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1116668545
    126 https://doi.org/10.1007/s12325-019-00965-y
    127 schema:sdDatePublished 2022-12-01T06:39
    128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    129 schema:sdPublisher Nad4c956f1688430a9803e1660d3dfc84
    130 schema:url https://doi.org/10.1007/s12325-019-00965-y
    131 sgo:license sg:explorer/license/
    132 sgo:sdDataset articles
    133 rdf:type schema:ScholarlyArticle
    134 N23e98cdd0fe745558a4a3daaa27222ea schema:issueNumber 8
    135 rdf:type schema:PublicationIssue
    136 N298473d0866842a688c479fa361a16c4 rdf:first sg:person.0670735136.94
    137 rdf:rest N2ebe41c4edfc4fe585c588a6be808cc1
    138 N2ebe41c4edfc4fe585c588a6be808cc1 rdf:first sg:person.01346701147.33
    139 rdf:rest rdf:nil
    140 N3231159448fd4e94b93dee5768f2786a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Slovakia
    142 rdf:type schema:DefinedTerm
    143 N329df857bc6e4dc5a013cea18d759328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Adult
    145 rdf:type schema:DefinedTerm
    146 N3dedb1d5490b439793eca376ac3011d3 rdf:first sg:person.01340720514.56
    147 rdf:rest N55ba63139f1246309f28213e59cae4ad
    148 N4eb61e2871fb4701b32463e74bfb93b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Female
    150 rdf:type schema:DefinedTerm
    151 N4f4357ffd1394a4f832527e78edccf0b schema:name pubmed_id
    152 schema:value 31168765
    153 rdf:type schema:PropertyValue
    154 N55ba63139f1246309f28213e59cae4ad rdf:first sg:person.01024046656.22
    155 rdf:rest N298473d0866842a688c479fa361a16c4
    156 N6638f62d50674f30bd0f5341cbea8cc0 schema:name dimensions_id
    157 schema:value pub.1116668545
    158 rdf:type schema:PropertyValue
    159 N748f7a61d71a43478bafc8aa41180d23 rdf:first sg:person.012067446720.22
    160 rdf:rest N3dedb1d5490b439793eca376ac3011d3
    161 N80a55e1915d74102b6d5a0be9d2d8286 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Drug Administration Schedule
    163 rdf:type schema:DefinedTerm
    164 N818a3ee2e6de409698ca3e929279e3d9 schema:name doi
    165 schema:value 10.1007/s12325-019-00965-y
    166 rdf:type schema:PropertyValue
    167 N9c0cf136c97b4d82ac33169b8148b7bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Aged, 80 and over
    169 rdf:type schema:DefinedTerm
    170 Na10f01d6ea9740e09f662a3c87c399b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Glucagon-Like Peptides
    172 rdf:type schema:DefinedTerm
    173 Na37e9e308a914f60af4911b2ae55da79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Cost-Benefit Analysis
    175 rdf:type schema:DefinedTerm
    176 Nad4c956f1688430a9803e1660d3dfc84 schema:name Springer Nature - SN SciGraph project
    177 rdf:type schema:Organization
    178 Nae4c0ccc6d7d428ba632c084663d5cce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Male
    180 rdf:type schema:DefinedTerm
    181 Nc8328a6118cd44859f00e0fb0c31bf46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Diabetes Mellitus, Type 2
    183 rdf:type schema:DefinedTerm
    184 Nd4e02989863345c78d0dc3f3ac6023b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Middle Aged
    186 rdf:type schema:DefinedTerm
    187 Nf8379dfd7a194836b900d041b8bd0984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Aged
    189 rdf:type schema:DefinedTerm
    190 Nfd965906c81b4efcb4ccd466cf24727b schema:volumeNumber 36
    191 rdf:type schema:PublicationVolume
    192 Nfde9cb48794d4828aaa403c95de304a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Humans
    194 rdf:type schema:DefinedTerm
    195 Nfe8b3ad33bee40fbb2de48169fa3b81d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Hypoglycemic Agents
    197 rdf:type schema:DefinedTerm
    198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    199 schema:name Medical and Health Sciences
    200 rdf:type schema:DefinedTerm
    201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Clinical Sciences
    203 rdf:type schema:DefinedTerm
    204 sg:journal.1096634 schema:issn 0741-238X
    205 1865-8652
    206 schema:name Advances in Therapy
    207 schema:publisher Springer Nature
    208 rdf:type schema:Periodical
    209 sg:person.01024046656.22 schema:affiliation grid-institutes:None
    210 schema:familyName Psota
    211 schema:givenName Marek
    212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024046656.22
    213 rdf:type schema:Person
    214 sg:person.012067446720.22 schema:affiliation grid-institutes:None
    215 schema:familyName Malkin
    216 schema:givenName Samuel J. P.
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
    218 rdf:type schema:Person
    219 sg:person.01340720514.56 schema:affiliation grid-institutes:None
    220 schema:familyName Russel-Szymczyk
    221 schema:givenName Monika
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340720514.56
    223 rdf:type schema:Person
    224 sg:person.01346701147.33 schema:affiliation grid-institutes:None
    225 schema:familyName Hunt
    226 schema:givenName Barnaby
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
    228 rdf:type schema:Person
    229 sg:person.0670735136.94 schema:affiliation grid-institutes:None
    230 schema:familyName Hlavinkova
    231 schema:givenName Lucia
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670735136.94
    233 rdf:type schema:Person
    234 sg:pub.10.1007/pl00002934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048891551
    235 https://doi.org/10.1007/pl00002934
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1007/s00125-002-0858-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1015709744
    238 https://doi.org/10.1007/s00125-002-0858-x
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
    241 https://doi.org/10.1007/s00125-004-1527-z
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1007/s00125-009-1472-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013300593
    244 https://doi.org/10.1007/s00125-009-1472-y
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1007/s00125-014-3460-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538250
    247 https://doi.org/10.1007/s00125-014-3460-0
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1007/s11136-014-0712-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041603789
    250 https://doi.org/10.1007/s11136-014-0712-x
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1007/s13300-017-0239-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083855326
    253 https://doi.org/10.1007/s13300-017-0239-6
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1007/s13300-018-0424-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103465312
    256 https://doi.org/10.1007/s13300-018-0424-2
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1007/s41669-019-0131-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113109417
    259 https://doi.org/10.1007/s41669-019-0131-6
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
    262 https://doi.org/10.1186/1477-7525-11-90
    263 rdf:type schema:CreativeWork
    264 grid-institutes:None schema:alternateName Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland
    265 Novo Nordisk Slovakia s.r.o, Bratislava, Slovakia
    266 Ossian Health Economics and Communications, Basel, Switzerland
    267 Pharm-In spol. s.r.o, Bratislava, Slovakia
    268 schema:name Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland
    269 Novo Nordisk Slovakia s.r.o, Bratislava, Slovakia
    270 Ossian Health Economics and Communications, Basel, Switzerland
    271 Pharm-In spol. s.r.o, Bratislava, Slovakia
    272 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...